Cat Financial Announces Second-Quarter 2020 Results

dnrt8765

NASHVILLE, Tenn., July 31, 2020 /PRNewswire/ — Cat Financial reported second-quarter 2020 revenues of $641 million, a decrease of $116 million, or 15%, compared with the second quarter of 2019. Second-quarter 2020 profit was $59 million, a $20 million, or 25%, decrease from the second quarter of 2019.

The decrease in revenues was primarily due to a $60 million unfavorable impact from lower average financing rates and a $48 million unfavorable impact from lower average earning assets.

Second-quarter 2020 profit before income taxes was $89 million, a $52 million, or 37%, decrease from

Hillrom Reports Strong Third Quarter Financial Results

dnrt8765

CHICAGO, July 31, 2020 /PRNewswire/ — Hillrom (NYSE: HRC) today announced financial results for its fiscal third quarter ended June 30, 2020 and provided commentary on current business trends and outlook.

For the fiscal third quarter, Hillrom reported earnings of $1.40 per diluted share compared to $0.48 per diluted share in the prior-year period. On an adjusted basis, excluding special items, earnings of $1.95 per diluted share rose 59 percent from $1.23 per diluted share in the prior-year period. Third quarter financial results reflect strong revenue that benefited from COVID-related purchases, strategic investments to drive future growth, disciplined cost

ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results

dnrt8765

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2020.

“Despite the challenges of operating in a fully remote environment due to the pandemic, our performance in the second quarter was marked by sound execution and important data presentations and regulatory milestones,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “In an oral presentation at ASCO, we shared data demonstrating the potential of mirvetuximab to serve as

Agios Reports Business Highlights and Second Quarter 2020 Financial Results

dnrt8765

The MarketWatch News Department was not involved in the creation of this content.

CAMBRIDGE, Jul 30, 2020 (GLOBE NEWSWIRE via COMTEX) —
– Second Quarter TIBSOVO(R) Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO(R) Net U.S. Revenue Guidance of $105-115 Million –

– Significant Clinical Progress for First-in-Class PKR Activator Mitapivat: Established Proof-of-Concept in Sickle Cell Disease; Presented Phase 2 Data in α- and B-Thalassemia; Pivotal Programs to be Initiated in 2021 –

– $255 Million Sale of IDHIFA(R) Royalty Extends Cash Runway, Inclusive of Thalassemia and Sickle Cell Disease Pivotal Development, through the End of